Sleep Deprivation Linked to Career Loss; Cancer Drug Funding Debated

New research indicates that significant sleep disruption can lead to a loss of up to nine months of working life for individuals over 50, with women showing a longer potential working life if they experience no sleep disturbances. This highlights the critical impact of sleep health on career longevity, particularly for those in middle age and with lower socioeconomic status.

In parallel, experts are recommending that the Australian government fund a drug, Triptorelin, for treating breast cancer, endometriosis, and gender dysphoria. This recommendation comes after a pharmaceutical company announced it would remove a similar drug from the market, potentially leaving thousands of women without treatment options. The debate underscores the complex interplay between medical research, drug accessibility, and public health funding.